Merck wins patent fight on Zetia, Vytorin; Fitch warns of 'pure pharma' risks;

 @FiercePharma: Oral drugs don't work well in kids with obesity-related Type 2 diabetes. Their disease is hard to treat, period--NYTArticle | Follow @FiercePharma

> A U.S. court upheld Merck's ($MRK) patent on the active ingredient ezetimibe, marketed as the cholesterol-lowering Zetia and in the combo cholesterol pill Vytorin. Report

> Fitch Ratings says drugmakers that focus purely on pharmaceuticals, such as AstraZeneca ($AZN), Bristol-Myers Squibb ($BMY) and Eli Lilly ($LLY) are likely to see the most pressure on sales and earnings in the near term than more diversified companies such as Bayer. News

> Novo Nordisk ($NVO) Vice Chairman Goran Ando is expected to take over the chairman's post at next year's annual meeting. Item

> Baxter International ($BAX) said a study showed its Gammagard Liquid, approved for use in adults and children with primary humoral immunodeficiency, benefited patients with multifocal motor neuropathy. More

> Watson Pharmaceuticals ($WPI) beat analyst estimates with quarterly profits of $54.8 million, aided by generic versions of the Pfizer ($PFE) cholesterol pill Lipitor and Sanofi ($SNY) blood thinner Lovenox. Article

> Children with Type 2 diabetes linked to obesity are harder to treat than adults with the same disease, with some oral drugs offering limited benefit. Story

> Faes Farma inked a commercialization deal with Invida Holdings that will push its antihistamine bilastine into 17 Asia-Pacific markets. Report

Biotech News

 @FierceBiotech: BT touts cloud for biopharma R&D collaboration, launches new service: BT for Life Sciences R&D. Story | Follow @FierceBiotech

 @JohnCFierce: Right now just about any positive news for a biotech company is greeted with speculation of a buyout. That often works for bad news as well. | Follow @JohnCFierce

 @RyanMFierce: In case you missed it Friday, here's my slide show of my biotech IT trip to Boston last week. Report | Follow @RyanMFierce

 @MarkHFierce: Hologic grabbed Gen-Probe for $3.7B: The prize: Hologic gains more tests for sexually transmitted diseases. News | Follow @MarkHFierce

> VC group offers to help axed Merck KGaA staffers launch spinoffs. Item

> 2012: Year of the dealmaker in biopharma. Analysis

> Biotech venture rounds dwindle in Europe, tracking U.S. trend. Report

> Actelion surges as positive PhIII macitentan data reignites buyout buzz. More

Medical Devices News

 @FierceMedDev: Vascular Solutions CEO Howard Root: Practical steps to help the device industry | StarTribune.comArticle | Follow @FierceMedDev

> Covidien acquires Israeli maker of hernia mesh placement device. Article

> Skin health company PhotoMedex grabs $40M in stock offering. News

> UCLA develops compact rapid diagnostic compatible with cellphones. Story

Biotech IT News

> Pfizer, Roche raise online profiles as GSK's drops. More

> Illumina to open app store for genomics, releases iPad app. News

> FDA's CIO pushes for open source, cloud computing. Story

> BT touts cloud for biopharma R&D collaboration. Article

And Finally... Fearful cancer patients gain relief from their anxieties with "magic mushrooms" ingredient. Report

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.